Insulin icodec is an ultra long-acting basal insulin analogue for once-weekly injection in patients with diabetes mellitus. It is a re-engineered version of the ultra long-acting oral basal insulin OI338, with several modifications introduced to significantly extend the half-life.
- Mechanism
- Curator reviewed · 8 references
Insulin and its analogues, including insulin icodec, lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Insulin icodec is modified in order to extend its half-life and, subsequently, its viable dosing interval. The fatty diacid component was changed from a 1,18-octadecanedioic acid (C18) to a 1,20-icosanedioic acid (C20), allowing for increased albumin binding which results in a depot effect in the circulation. In addition, an amino acid deletion (ThrB30) and three amino acid substitutions (A14Tyr -> Glu, B16Tyr -> His, B25Phe -> His) result in attenuated insulin receptor affinity that further extends its half-life.
- Primary indication
- Insulin icodec is indicated for the once-weekly treatment of adults with diabetes mellitus in order to improve glycemic control.Curator reviewed · 5 structured indications
- Formula / weight
- 6380.26 Da
- First approval
- Canada, 2024 · United States, 2026 · European Union, 2024
- Also known as
- Insulin 287
- Brand names
Resolves to
What you can answer from here — as of April 07, 2026
Which drugs share a target with Insulin icodec, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account